Can ENHANCE Diminish Vytorin? Schering, Merck Minimize Trial’s Importance

Schering-Plough and Merck are downplaying the significance of upcoming results from the ENHANCE trial comparing Vytorin (ezetimibe/simvastatin) to simvastatin alone in inhibiting atherosclerosis of the carotid artery